Is this your company? Get featured or correct your listing →
Key Metrics
Recent changes
- Sep 21, 2026Sep 21, 2026IPO $350M Cooley
- Sep 21, 2026Sep 21, 2026First reported total funding: ~$401.2M Cooley
- Sep 21, 2026Sep 21, 2026Electra Therapeutics Closes First Day Down 12% Pulse story
Funding History
2 events · sources dated per row| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Sep 21, 2026 | ipo | $350M | — | Cooley | |
| funding round | $341.9M | — | Fierce Biotech |
Investors
Latest Pulse
- Sep 25, 2026The Fall 2026 IPO Window, By The Numbers2026's IPO market has priced 109 offerings raising $146.5 billion through mid-September, and this week's cohort -- a mix of pops, declines and a pulled listing -- shows the window staying open but increasingly selective.→
- Sep 25, 2026This Week's IPO Class Delivered A Split VerdictThe same week produced a 19% pop for Ligent, a 12% decline for Electra Therapeutics, and a pulled listing for Bamboo Insurance -- evidence the 2026 IPO window is open but pricing power now depends entirely on the individual deal.→
- Sep 22, 2026Oura Sets $40-$44 Price Range, Trading Starts Next WeekOura launched its IPO roadshow with a $40-$44 price range targeting a $15.62 billion valuation, with Nasdaq trading expected the week of September 28, and disclosed revenue of $1.21 billion over nine months, up 74% year over year.→
- Sep 22, 2026Why Some Fall IPOs Are Filing While Others Are PricingThis fall's IPO pipeline is splitting between companies actually pricing and trading -- newcleo, Electra Therapeutics -- and a growing backlog of filed-but-not-priced names including Nscale and Wella, some sitting for weeks without terms.→
- Sep 22, 2026This Fall's Biotech IPOs Are Splitting Into Pops And DropsRecent biotech IPO debuts have split sharply: Parabilis Medicines popped 66.75% and BillionToOne jumped 66.67% on debut, while Electra Therapeutics closed down nearly 12% this week -- a mixed signal inside one reopened window.→
- Sep 21, 2026AbbVie-Backed ADARx Sets Terms For $350M Nasdaq IPOADARx Pharmaceuticals set terms for a $350 million IPO at $15 to $17 a share, seeking to fund Phase 2 trials of its lead siRNA therapy for rare renal disease, after posting an $87.7 million net loss on $6.1 million of collaboration revenue.→
- Sep 21, 2026Electra Therapeutics Closes First Day Down 12%Electra Therapeutics priced its upsized IPO at $15 a share for roughly $350 million, then closed its first trading day on Nasdaq down nearly 12% at $13.25 -- a rockier debut than the biotech IPO market's recent run of first-day pops.→
- Sep 21, 2026Nvidia, Qatar-Backed AI Drug Startup Iambic Files For IPOIambic Therapeutics, an AI-driven drug discovery company backed by Nvidia and Qatar's sovereign wealth fund, filed for a US IPO at a roughly $5.49 billion market cap amid a busy fall pipeline of AI-adjacent biotechs.→
- Sep 21, 2026Bamboo Insurance's IPO Won't Give The Company A DollarBamboo Insurance is marketing 35 million shares at $18-$20 for its NYSE debut under ticker BMB, but every share is being sold by backers CVC Capital Partners and White Mountains -- the company gets no proceeds.→
- Sep 14, 2026Why 2026 Has Fewer IPOs Than 2025 Despite Bigger OnesValue Add Pulse compared the 2026 US listing tally with 2025 and found slightly fewer deals despite record-sized offerings, a mix shift toward large asset-heavy issuers rather than a broad reopening.→
Coverage Timeline
newest first- Sep 25, 2026IPOThis Week's IPO Class Delivered A Split Verdict→
- Sep 22, 2026IPOWhy Some Fall IPOs Are Filing While Others Are Pricing→
- Sep 22, 2026IPOThis Fall's Biotech IPOs Are Splitting Into Pops And Drops→
- Sep 21, 2026IPOElectra Therapeutics Closes First Day Down 12%$350M raised→
- Sep 14, 2026IPOThree IPOs Set Terms In A $2.1B Week~$2.1B combined→
All Coverage
IPO
This Week's IPO Class Delivered A Split Verdict
The same week produced a 19% pop for Ligent, a 12% decline for Electra Therapeutics, and a pulled listing for Bamboo Insurance -- evidence the 2026 IPO window is open but pricing power now depends entirely on the individual deal.
DEEP DIVE
Why Some Fall IPOs Are Filing While Others Are Pricing
IPO
Why Some Fall IPOs Are Filing While Others Are Pricing
This fall's IPO pipeline is splitting between companies actually pricing and trading -- newcleo, Electra Therapeutics -- and a growing backlog of filed-but-not-priced names including Nscale and Wella, some sitting for weeks without terms.
DEEP DIVE
This Fall's Biotech IPOs Are Splitting Into Pops And Drops
IPO
This Fall's Biotech IPOs Are Splitting Into Pops And Drops
Recent biotech IPO debuts have split sharply: Parabilis Medicines popped 66.75% and BillionToOne jumped 66.67% on debut, while Electra Therapeutics closed down nearly 12% this week -- a mixed signal inside one reopened window.
BY THE NUMBERS
Electra Therapeutics Closes First Day Down 12%
IPO$350M raised
Electra Therapeutics Closes First Day Down 12%
Electra Therapeutics priced its upsized IPO at $15 a share for roughly $350 million, then closed its first trading day on Nasdaq down nearly 12% at $13.25 -- a rockier debut than the biotech IPO market's recent run of first-day pops.
FOLLOW-UP
Three IPOs Set Terms In A $2.1B Week
IPO~$2.1B combined
Three IPOs Set Terms In A $2.1B Week
Holtec Nuclear, Bamboo Insurance and Electra Therapeutics set IPO terms within a day of each other, lining up roughly $1.8 billion of supply; with Orion180's $320 million deal, the week's calendar totals about $2.1 billion.
FOLLOW-UP
Value Add Research
Related Companies
Electra Therapeutics FAQ
How much has Electra Therapeutics raised?
Electra Therapeutics has raised ~$401.2M in total funding (As of Sep 21, 2026, Cooley).
Who are Electra Therapeutics's investors?
Electra Therapeutics's investors include New Leaf Venture Partners (As of Sep 21, 2026).
Sources & methodologyshow
Where these figures come from
- Fierce Biotechmajor outlet1 fact
- CooleyValue Add VC data2 facts
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.